Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, the next ...

A federal jury in Delaware has awarded Regeneron (NASDAQ:REGN) more than $400M in damages after finding that Amgen ...

Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company") today reported financial results for the first quarter ...

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced that an abstract regarding ...

Slow progress, pipeline uncertainty & lack of catalysts weigh despite strong cash. Click to read why KYMR stock is a Hold.

Sanofi plans $20 billion US investment by 2030 to expand R&D and manufacturing, aiming to boost medicine production and job ...

Sanofi (SNY) commits $20B to U.S. research & manufacturing by 2030, boosting R&D & partnerships amidst industry-wide ...

The French drugmaker, one of the world's largest vaccine makers and a leader in anti-inflammatory drugs, said on Wednesday it ...

French drugmaker Sanofi said on Wednesday it plans to invest at least $20 billion in the United States through 2030, which ...

Sanofi today announces its intention to invest at least $20 billion in the United States through 2030. The expected investment includes a significant increase in research and development spending and ...

Analysts are still crunching the numbers on the impact of President Donald Trump's executive order from Monday on drug pricing. HSBC analyst Rajesh Kumar says a 20% price cut in government channels ...

Swedish biotech Hansa Biopharma (Nasdaq Stockholm: HNSA) has appointed Maria Törnsén as chief operating officer and president ...